Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
2020;104(4S1 Suppl 1):S11103
This information can support conversations with your provider about personalized expectations, potential titration strategies, and monitoring approaches
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
Consult a Healthcare Professional Before starting semaglutide, schedule a consultation with a healthcare provider who specializes in weight management
Track your usage patterns and order quantities that match your actual consumption to minimize waste
Natural GLP-1 secretion in the body follows a circadian pattern
